A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Status:
Recruiting
Trial end date:
2025-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ustekinumab compared to placebo, in
combination with oral glucocorticoid (GC) taper regimen, in participants with relapsing
Takayasu Arteritis (TAK).